Udo Albus

4.5k total citations · 3 hit papers
29 papers, 3.9k citations indexed

About

Udo Albus is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Udo Albus has authored 29 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 12 papers in Molecular Biology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Udo Albus's work include Cardiac electrophysiology and arrhythmias (11 papers), Cardiac Ischemia and Reperfusion (7 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Udo Albus is often cited by papers focused on Cardiac electrophysiology and arrhythmias (11 papers), Cardiac Ischemia and Reperfusion (7 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers). Udo Albus collaborates with scholars based in Germany, France and United States. Udo Albus's co-authors include Bernward A. Schölkens, Wolfgang Linz, Klaus Wirth, Gerhard Breipohl, Jochen Knolle, Wilfried Α. König, Franz J. Hock, Wolfgang Scholz, Gabriele Wiemer and H. G. Alpermann and has published in prestigious journals such as Journal of Neurochemistry, British Journal of Pharmacology and Biochemical Pharmacology.

In The Last Decade

Udo Albus

29 papers receiving 3.7k citations

Hit Papers

Guide for the Care and Use of Lab... 1991 2026 2002 2014 2012 1991 1991 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Guide for the Care and Use of Laboratory Animals (8th edn)
    2012 1.5k citations Udo Albus profile →
  2. Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivostudies
    1991 742 citations Klaus Wirth, Franz J. Hock et al. British Journal of Pharmacology profile →
  3. Hoe 140 a new potent and long acting bradykinin‐antagonist:in vitrostudies
    1991 533 citations Franz J. Hock, Klaus Wirth et al. British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Udo Albus Germany 17 1.4k 1.0k 851 584 527 29 3.9k
Raymond P. Roos United States 48 2.1k 1.6× 942 0.9× 1.6k 1.9× 912 1.6× 409 0.8× 170 6.6k
Mohan Viswanathan United States 35 2.1k 1.6× 191 0.2× 1.3k 1.5× 339 0.6× 272 0.5× 110 5.5k
Kai Xu United States 30 1.3k 0.9× 258 0.3× 406 0.5× 481 0.8× 391 0.7× 85 3.4k
Carl M. Pearson United States 51 2.7k 2.0× 1.6k 1.6× 488 0.6× 670 1.1× 633 1.2× 180 10.7k
Hugo R. de Jonge Netherlands 54 4.6k 3.4× 256 0.3× 589 0.7× 559 1.0× 289 0.5× 186 9.2k
Takahiro Suzuki Japan 40 1.7k 1.3× 421 0.4× 212 0.2× 461 0.8× 269 0.5× 294 6.4k
Noor Kalsheker United Kingdom 34 2.0k 1.5× 344 0.3× 234 0.3× 131 0.2× 143 0.3× 114 5.1k
John W. Hanrahan Canada 56 4.4k 3.3× 248 0.2× 316 0.4× 731 1.3× 841 1.6× 170 10.0k
Gabriele Schoedon Switzerland 35 1.4k 1.1× 233 0.2× 163 0.2× 139 0.2× 280 0.5× 78 3.8k
Rochelle Hirschhorn United States 48 3.2k 2.4× 307 0.3× 193 0.2× 279 0.5× 430 0.8× 151 7.1k

Countries citing papers authored by Udo Albus

Since Specialization
Citations

This map shows the geographic impact of Udo Albus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udo Albus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udo Albus more than expected).

Fields of papers citing papers by Udo Albus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udo Albus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udo Albus. The network helps show where Udo Albus may publish in the future.

Co-authorship network of co-authors of Udo Albus

This figure shows the co-authorship network connecting the top 25 collaborators of Udo Albus. A scholar is included among the top collaborators of Udo Albus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udo Albus. Udo Albus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jung, Oliver, Udo Albus, Hans‐Jochen Lang, Andreas Büsch, & Wolfgang Linz. (2004). Effects of Acute and Chronic Treatment with the Sodium Hydrogen Exchanger 1 (NHE‐1) Inhibitor Cariporide on Myocardial Infarct Mass in Rabbits with Hypercholesterolaemia. Basic & Clinical Pharmacology & Toxicology. 95(1). 24–30. 8 indexed citations
2.
Gögelein, Heinz, Hartmut Ruetten, Udo Albus, Heinrich Englert, & Andreas Büsch. (2001). Effects of the cardioselective K ATP channel blocker HMR 1098 on cardiac function in isolated perfused working rat hearts and in anesthetized rats during ischemia and reperfusion. Naunyn-Schmiedeberg s Archives of Pharmacology. 364(1). 33–41. 29 indexed citations
3.
Scholz, Wolfgang, Andreas Jessel, & Udo Albus. (1999). Development of the Na+/H+ Exchange Inhibitor Cariporide as a Cardioprotective Drug: From the Laboratory to the GUARDIAN Trial. Journal of Thrombosis and Thrombolysis. 8(1). 61–70. 17 indexed citations
4.
Linz, Wolfgang, et al.. (1998). Dose-Dependent Reduction of Myocardial Infarct Mass in Rabbits by the NHE-1 Inhibitor Cariporide (HOE 642). Clinical and Experimental Hypertension. 20(7). 733–749. 64 indexed citations
5.
Scholz, Wolfgang, Udo Albus, Hans‐Jochen Lang, et al.. (1993). Hoe 694, a new Na+/H+ exchange inhibitor and its effects in cardiac ischaemia. British Journal of Pharmacology. 109(2). 562–568. 159 indexed citations
6.
Scholz, Wolfgang & Udo Albus. (1993). Na+/H+ exchange and its inhibition in cardiac ischemia and reperfusion. Basic Research in Cardiology. 88(5). 443–455. 68 indexed citations
7.
Englert, Heinrich, Klaus Wirth, Doris Gehring, et al.. (1992). Airway pharmacology of the potassium channel opener, HOE 234, in guinea pigs: in vitro and in vivo studies. European Journal of Pharmacology. 210(1). 69–75. 23 indexed citations
8.
Linz, Wolfgang, Jutta Schaper, Gabriele Wiemer, Udo Albus, & Bernward A. Schölkens. (1992). Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. British Journal of Pharmacology. 107(4). 970–975. 104 indexed citations
9.
Greenbaum, Lowell M., Eugene F. Howard, Udo Albus, Carol A. Lapp, & Xing Gao. (1992). T-Kininogen, Processing and Functions. Birkhäuser Basel eBooks. 38 ( Pt 1). 300–306. 6 indexed citations
10.
Albus, Udo, et al.. (1992). Lack of specific binding of bradykinin and D-Arg [Hyp3, Thi5, D-Tic, Oic8] bradykinin in membranes from rat heart.. PubMed. 38 ( Pt 3). 73–9. 2 indexed citations
11.
Linz, Wolfgang, et al.. (1992). Cardiovascular effects of the novel potassium channel opener (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxo- 1-pyrrolidinyl)-6-phenylsulfonylchromane hemihydrate.. PubMed. 42(10). 1180–5. 8 indexed citations
12.
Wirth, Klaus, Franz J. Hock, Udo Albus, et al.. (1991). Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivostudies. British Journal of Pharmacology. 102(3). 774–777. 742 indexed citations breakdown →
13.
Hock, Franz J., Klaus Wirth, Udo Albus, et al.. (1991). Hoe 140 a new potent and long acting bradykinin‐antagonist:in vitrostudies. British Journal of Pharmacology. 102(3). 769–773. 533 indexed citations breakdown →
14.
Linz, Wolfgang, et al.. (1989). Cardiac arrhythmias are ameliorated by local inhibition of angiotensin formation and bradykinin degradation with the converting-enzyme inhibitor ramipril. Cardiovascular Drugs and Therapy. 3(6). 873–882. 26 indexed citations
15.
Becker, R. H. A., Udo Albus, Wolfgang Linz, et al.. (1989). High-Affinity Binding of the Converting Enzyme Inhibitor, Ramiprilat, to Isolated Human Glomeruli. Journal of Cardiovascular Pharmacology. 13. S31–S34. 1 indexed citations
16.
Linz, Wolfgang, Udo Albus, & Bernward A. Schölkens. (1989). Effects of endothelin on isolated ischaemic rat hearts during ramiprilat, bradykinin and indomethacin perfusion. Journal of Hypertension. 7(6). S310–311. 6 indexed citations
17.
Linz, Wolfgang, Udo Albus, Gabriele Wiemer, et al.. (1988). Amiloride potentiates the vascular effects of atrial natriuretic factor. Journal of Hypertension. 6(4). S300–302. 3 indexed citations
18.
Albus, Udo, et al.. (1988). High affinity binding of ramiprilat on isolated human glomeruli. Biochemical Pharmacology. 37(24). 4679–4684. 1 indexed citations
19.
Albus, Udo, E. Habermann, David Ferry, & Hartmut Glossmann. (1984). Novel 1,4‐Dihydropyridine (Bay K 8644) Facilitates Calcium‐Dependent [3H]Noradrenaline Release from PC 12 Cells. Journal of Neurochemistry. 42(4). 1186–1189. 52 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raymond P. Roos Breakdown of academic impact, for papers by Mohan Viswanathan Breakdown of academic impact, for papers by Kai Xu Breakdown of academic impact, for papers by Carl M. Pearson Breakdown of academic impact, for papers by Hugo R. de Jonge Breakdown of academic impact, for papers by Takahiro Suzuki Breakdown of academic impact, for papers by Noor Kalsheker Breakdown of academic impact, for papers by John W. Hanrahan Breakdown of academic impact, for papers by Gabriele Schoedon Breakdown of academic impact, for papers by Rochelle Hirschhorn
Rankless by CCL
2026